CVL006
Phase 2Small molecule
CVL006 is one of 60 small molecule programs targeting Advanced Solid Tumors. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
311 competitors in Advanced Solid Tumors
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Opdivo
Bristol-Myers SquibbPhase 2
Paraplatin
AAvyxa
Phase 2
Tecentriq
RochePhase 2
Beyfortus
BeiGenePhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Erbitux
IImclone
Phase 2
Braftovi
PfizerPhase 2
Sutent
PfizerPhase 2
Tarceva
OOSI Pharmaceuticals
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Rare Tumor1 trial
Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)
Not yet recruiting·—·Phase 1/2·NCT07307053·600 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CVL006. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CConvalife (Shanghai) Co., Ltd.